文献速递免疫规划

15价肺炎球菌结合疫苗在日本健康婴儿中的安全性与免疫原性:一项III期研究(V114-033)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A phase III study (V114-033).
PubMed 文献 · Vaccine · 2023-06-19

这项III期研究将694名日本健康婴儿随机分配至V114组(n=347)或PCV13组(n=347),接受三剂基础免疫及一剂幼儿加强免疫。V114对13个共有血清型达到非劣效标准,对22F血清型达到非劣效标准,对33F血清型非劣效标准未达到(90.9%,双侧95%CI下限-10.6)。V114总体耐受性良好,对22F和33F的免疫应答高于PCV13。

要点

  • V114对13个共有血清型的免疫应答非劣效于PCV13。
  • V114对22F血清型达到非劣效标准,对33F血清型未达到。
  • V114组与PCV13组征集性不良事件和严重不良事件比例相当。

核心结论

  • 在日本婴儿中,四剂次V114系列总体耐受性良好;与PCV13相比,V114对13个共有血清型提供非劣效免疫应答,基础免疫后对22F和33F血清型提供更高的免疫应答。

研究设计与样本

  • III期研究,健康日本婴儿随机接受三剂基础剂次V114或PCV13(第1剂在2-6月龄;第2、3剂在先前剂次后≥27天),并在12-15月龄接受幼儿剂次;共694名婴儿随机分配至V114组(n=347)或PCV13组(n=347)。

主要发现

  • V114组与PCV13组征集性不良事件和严重不良事件的比例相当;V114在第3剂后30天对全部13个共有血清型达到非劣效标准(应答者比例差异的双侧95%CI下限>-10.0;IgG GMC比值V114/PCV13的双侧95%CI下限>0.5);基于IgG应答率的非劣效标准对22F血清型达到,对33F血清型未达到(90.9%,双侧95%CI下限-10.6)。

关键数值与推荐

  • 第3剂后30天,13个共有血清型的应答者比例差异双侧95%CI下限>-10.0;IgG GMC比值(V114/PCV13)双侧95%CI下限>0.5;22F血清型基于IgG应答率非劣效标准达到;33F血清型未达到(90.9%,双侧95%CI下限-10.6)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This phase III study evaluated safety, tolerability, and immunogenicity of V114 (15-valent pneumococcal conjugate vaccine) in Japanese infants. V114 contains all 13 serotypes in PCV13 plus additional serotypes 22F and 33F. METHODS: Healthy Japanese infants were randomized to receive three primary doses of V114 or PCV13 (dose 1 at 2-6 months of age; doses 2 and 3 ≥ 27 days after prior dose), plus a toddler dose at 12-15 months of age. Adverse events (AEs) were collected on Days 1-14 following each vaccination. Serotype-specific anti-pneumococcal immunoglobulin G (IgG) was measured 30 days post-dose 3, pre-dose 4, and 30 days post-dose 4. Primary objectives included non-inferiority of V114 to PCV13 for the 13 shared serotypes based on serotype-specific IgG response rates (IgG ≥ 0.35 μg/mL) and geometric mean concentration (GMC) ratios, and for serotypes 22F and 33F based on IgG response rates and compared with the lowest response of any serotype in the PCV13 group, at 30 days post-dose 3. RESULTS: Overall, 694 infants were randomized to V114 (n = 347) or PCV13 (n = 347). Proportions of participants with solicited and serious AEs were comparable between vaccination groups. V114 met non-inferiority criteria for all 13shared serotypes, based on difference in proportion of responders (lower bound of two-sided 95 % confidence interval [CI] > -10.0) and IgG GMC ratios (V114/PCV13, lower bound of two-sided 95 % CI > 0.5) at 30 days post-dose 3. The non-inferiority criterion based on IgG response rates was met for serotype 22F, but narrowly missed for serotype 33F (90.9 %, lower bound of two-sided 95 % CI -10.6). CONCLUSION: In Japanese infants, a four-dose series of V114 was generally well tolerated. Compared with PCV13, V114 provided non-inferior immune responses to the 13 shared serotypes and higher immune responses to serotype 22F and 33F post-primary series. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04384107; EudraCT 2019-003644-68.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Suzuki H, Fujita H, Iwai K, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A phase III study (V114-033). Vaccine. 2023. PMID: 37344262. doi:10.1016/j.vaccine.2023.05.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。